Global Cutaneous Radiation Injury Treatment Market Size study, By Exposure Type (Contamination, Irradiation), By Stage (Prodromal Stage, Latent Stage, Manifest Illness Stage, Third Wave of Erythema), By Route of Administration (Oral, Topical), By Drug Typ

Global Cutaneous Radiation Injury Treatment Market Size study, By Exposure Type (Contamination, Irradiation), By Stage (Prodromal Stage, Latent Stage, Manifest Illness Stage, Third Wave of Erythema), By Route of Administration (Oral, Topical), By Drug Type (Nonsteroidal anti-inflammatory drugs, Antihistamine, Antibiotics, Corticosteroids, Others), By Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Pharmacies, Mail Order Pharmacies), and Regional Forecasts 2022-2028

Global Cutaneous Radiation Injury Treatment Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Cutaneous Radiation Injury refers to skin injuries due to exposure to a large dose of radiation. CRIs major symptoms are – reddening of skin, darkening of skin (black or brown), itchy skin, dry and peeling skin. Radiation skin injury happens in various stages based on the dose to the skin and length of time exposed, with hair loss, skin rashes, dry and moist desquamation of skin, weeping eczema, and ulceration among others. Growing prevalence of acute skin reactions and increasing demand for oncology procedures. As well as favorable government initiatives are key drivers for growth of Cutaneous Radiation Injury Treatment Market. For instance, according to Statista - In 2021, global oncology spending was estimated at USD 187 billion. Spending is projected to increase to around USD 273 billion dollars by 2025 . Furthermore, in August 2019, The US Food and Drug Administration (FDA) granted Orphan Drug designation to Chrysalis BioTherapeutics, Inc.’s TP508 for treatment of acute radiation syndrome. TP508 is a regenerative peptide drug that stimulates repair skin tissues exhibits anti-inflammatory and anti-apoptotic effects on damaged cells and tissues. Also, growing prevalence of cancer and increasing technological advancements in healthcare sector are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost associated with Cutaneous Radiation Injury impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Cutaneous Radiation Injury Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to growing number of R&D activities in healthcare sector and presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing radiation treatment procedures and rising healthcare sector in the region, would create lucrative growth prospects for the Cutaneous Radiation Injury Treatment Market across the Asia Pacific region.

Major market players included in this report are:
Merck & Co.
Novartis AG
Johnson and Johnson
Pfizer Inc.
Amgen
Hoffmann-La Roche Ltd
Eli Lily and Company
AstraZeneca
Teva Pharmaceutical
Phokus Research Group Inc


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Exposure Type
Contamination
Irradiation
By Stage
Prodromal Stage
Latent Stage
Manifest Illness Stage
Third Wave of Erythema
By Route of Administration
Oral
Topical
By Drug Type
Nonsteroidal anti-inflammatory drugs
Antihistamine
Antibiotics
Corticosteroids
Others
By Distribution Channel
Hospitals Pharmacies
Drug Stores
Retail Pharmacies
Mail Order Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Cutaneous Radiation Injury Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors



Companies Mentioned

Merck & Co.
Novartis AG
Johnson and Johnson
Pfizer Inc.
Amgen
Hoffmann-La Roche Ltd
Eli Lily and Company
AstraZeneca
Teva Pharmaceutical
Phokus Research Group Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.